IL6 and breast carcinoma: Unravelling heterogeneous effects of cancer‐associated fibroblasts on poor prognosis markers in breast cancer EM‐G3 cell line: In vitro‐targeted treatment (anti‐IL-6, anti‐VEGF-A, anti‐MFGE8) based on transcriptomic profiling